Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
What to know about MIT professor Nuno Loureiro and the investigation into his shooting- Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- The Best Cell phone Brands for Tech Lovers
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- Spots to Go Hang Floating
- Crew-11 astronauts undock in 1st-ever medical evacuation from the International Space Station (video)
- Portable Installment Answers for Independent ventures
